Literature DB >> 17964915

Cardiovascular morbidity and mortality of the metabolic syndrome.

Kotaro Obunai1, Sonal Jani, George D Dangas.   

Abstract

Cardiovascular disease remains the single leading cause of morbidity and mortality in the United States. The metabolic syndrome has received increased attention in recent years, partly because of the growing prevalence of obesity and its association with cardiovascular disease. This article reviews current evidence from longitudinal observational studies that evaluated the impact of metabolic syndrome on cardiovascular morbidity and mortality in various population subsets. The approach to cardiovascular risk assessment in individuals who have multiple risk factors and the clinical implications of diagnosing the metabolic syndrome are also discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17964915     DOI: 10.1016/j.mcna.2007.06.003

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  28 in total

Review 1.  Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus.

Authors:  Srikanth Yandrapalli; Wilbert S Aronow
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

2.  Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.

Authors:  Arwa Younis; Anan Younis; Boaz Tzur; Yael Peled; Nir Shlomo; Ilan Goldenberg; Enrique Z Fisman; Alexander Tenenbaum; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2016-10-28       Impact factor: 9.951

3.  Divergence between arterial perfusion and fatigue resistance in skeletal muscle in the metabolic syndrome.

Authors:  Jefferson C Frisbee; Adam G Goodwill; Joshua T Butcher; I Mark Olfert
Journal:  Exp Physiol       Date:  2010-12-01       Impact factor: 2.969

4.  Predictive value of retroperitoneal fat area measurement for detecting metabolic syndrome in patients undergoing adrenalectomy.

Authors:  Feyzullah Ersöz; Yeşim Erbil; Serkan Sarı; Artür Salmaslıoğlu; Halim Işsever; Ferihan Aral; Selçuk Özarmağan
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

Review 5.  Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction.

Authors:  James W Yockman; Andrew Kastenmeier; Harold M Erickson; Jonathan G Brumbach; Matthew G Whitten; Aida Albanil; Dean Y Li; Sung Wan Kim; David A Bull
Journal:  J Control Release       Date:  2008-07-06       Impact factor: 9.776

6.  Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension.

Authors:  Sharon Barone; Stacey L Fussell; Anurag Kumar Singh; Fred Lucas; Jie Xu; Charles Kim; Xudong Wu; Yiling Yu; Hassane Amlal; Ursula Seidler; Jian Zuo; Manoocher Soleimani
Journal:  J Biol Chem       Date:  2008-12-17       Impact factor: 5.157

7.  Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Authors:  Hua Jin; Pei-an Betty Shih; Shahrokh Golshan; Sunder Mudaliar; Robert Henry; Danielle K Glorioso; Stephan Arndt; Helena C Kraemer; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

8.  SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Authors:  Muhammad Abdul-Ghani; Stefano Del Prato; Robert Chilton; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2016-05       Impact factor: 19.112

Review 9.  Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.

Authors:  Vasiliki Bistola; Vaia Lambadiari; George Dimitriadis; Ioannis Ioannidis; Konstantinos Makrilakis; Nikolaos Tentolouris; Apostolos Tsapas; John Parissis
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

10.  Kidney pathological changes in metabolic syndrome: a cross-sectional study.

Authors:  Mariam P Alexander; Tejas V Patel; Youssef M K Farag; Adriana Florez; Helmut G Rennke; Ajay K Singh
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.